Free tool
FAERS Monitor: Eylea Hd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761355 or its brand name (Eylea Hd, Aflibercept). Reports on generic versions are filed under their own applications.
Reports
4,671
Serious
4,088
88% of reports
Hospitalization
1,536
Death reported
439
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use506
- diarrhoea380
- visual acuity reduced221
- neutropenia215
- hypertension210
- endophthalmitis207
- visual impairment179
- vision blurred169
- asthenia155
- disease progression154
- drug ineffective153
- eye inflammation150
- eye pain132
- vitritis125
- nausea124
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 11 |
| 2010 | 45 |
| 2011 | 27 |
| 2012 | 57 |
| 2013 | 240 |
| 2014 | 162 |
| 2015 | 159 |
| 2016 | 180 |
| 2017 | 182 |
| 2018 | 532 |
| 2019 | 328 |
| 2020 | 212 |
| 2021 | 200 |
| 2022 | 170 |
| 2023 | 222 |
| 2024 | 505 |
| 2025 | 789 |
| 2026 | 643 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,488 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vitritisSignal | 125 | 326.0 | 272.5 | 37,467 |
| endophthalmitisSignal | 207 | 160.9 | 140.5 | 31,612 |
| eye inflammationSignal | 150 | 71.9 | 61.3 | 10,258 |
| visual acuity reducedSignal | 221 | 30.2 | 26.5 | 6,170 |
| eye painSignal | 132 | 10.6 | 8.9 | 1,133 |
| neutropeniaSignal | 215 | 7.1 | 6.3 | 1,132 |
| visual impairmentSignal | 179 | 6.5 | 5.6 | 833 |
| disease progressionSignal | 154 | 5.9 | 5.0 | 620 |
| vision blurredSignal | 169 | 5.5 | 4.8 | 629 |
| hypertensionSignal | 210 | 4.5 | 3.9 | 567 |
| diarrhoeaSignal | 380 | 2.7 | 2.4 | 401 |
| off label useSignal | 506 | 2.6 | 2.4 | 519 |
| asthenia | 155 | 1.9 | 1.6 | 61 |
| nausea | 124 | 0.7 | 0.6 | 16 |
| drug ineffective | 153 | 0.5 | 0.4 | 71 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.